SCHEMBL3369871

SCHEMBL3369871

CN(C)c1nc(-c2cccnc2)nc(-c2ccc(Cl)cc2)c1C#N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 1.00
KMT2A Q03164 4/20 1.00
MEN1 O00255 3/20 1.00
ALDH1A1 P00352 3/20 1.00
MAPK1 P28482 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
RXFP1 Q9HBX9 3/20 0.82
NPSR1 Q6W5P4 2/20 0.76
HPGD P15428 2/20 0.76
CYP1A2 P05177 1/20 0.48
GLA P06280 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
TSHR P16473 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48
ADORA1 P30542 3/20 0.46
ADORA2A P29274 3/20 0.46
NPY5R Q15761 1/20 0.44
ADORA2B P29275 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2400448 0.87 NPSR1 (1.00) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL3372299 0.79 RXFP1 (1.00) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL20570773 0.76 KMT2A (1.00) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL14474975 0.73 MEN1 (0.65) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL19885521 0.72 HPGD (0.74) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL23852855 0.71 KMT2A (0.71) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL31591781 0.71 KMT2A (0.71) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL23851984 0.71 KMT2A (0.71) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL14475106 0.70 MEN1 (0.54) KDM4EKMT2AMEN1ALDH1A1MAPK1
SCHEMBL14727832 0.68 CYP1A2 (0.61) KDM4EKMT2AMEN1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
CN-1324015-C Pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-07-04 CN disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
CN-1630644-A Novel pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2005-06-22 CN disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 KDM4E 1329/4885KMT2A 3893/4885MEN1 3734/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK KDM4E 916/4885KMT2A 3650/4885MEN1 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.